If there was ever a question about the importance of intellectual property (IP) and patent protection to the pharmaceutical industry, it is about to be answered. The world’s top drug makers are shuffling towards the edge of a patent cliff that may cost the industry £70 billion in annual sales by 2016, as key product patents expire and cheap generic versions of their blockbuster medicines hit the market.
The industry will no doubt survive the fall, but patents are likely to become even more important to corporations, as they reformulate their strategies and become more competitive and acquisitive. Those companies that spend the time and money up front on patent strategy and awareness are likely to emerge the strongest.





